| Literature DB >> 32066862 |
Yuhua Ru1,2,3, Xiang Zhang1,2,3, Tiemei Song1,2,3, Yiyang Ding1,2,3, Ziling Zhu1,2,3, Yi Fan1,2,3, Yang Xu1,2,3, Aining Sun1,2,3, Huiying Qiu1,2,3, Zhengming Jin1,2,3, Xiaowen Tang1,2,3, Yue Han1,2,3, Zhengzheng Fu1,2,3, Suning Chen1,2,3, Xiao Ma1,2,3, Feng Chen1,2,3, Jia Chen4,5,6, Depei Wu7,8,9.
Abstract
Epstein-Barr virus (EBV) reactivation after allogeneic hematopoietic cell transplantation (allo-HCT) is one of the major concerns that may lead to fatal EBV diseases. However, updated data are needed because of the remarkable evolution of the HCT protocol and donor selection. We conducted a retrospective study that enrolled 890 allo-HCT recipients. Independent risk factors for EBV reactivation were use of antithymocyte globulin, haploidentical donor, and the presence of chronic graft-versus-host disease. The cumulative incidence of EBV reactivation was 2.9%, 11.7%, 27.3%, and 41.9% for patients with 0, 1, 2, and 3 risk factors, respectively (P < 0.001). Posttransplant lymphoproliferative disorders (PTLDs) occurred in seven patients. EBV reactivation was associated with inferior survival in recipients who survived more than 2 years post-HCT (P < 0.001) but might time-dependently benefit those patients with malignancies by decreasing relapse incidence (P = 0.046). A decreased relapse incidence was observed 1 year after HCT for recipients at first or second remission (P = 0.042) and in the first year post-HCT for recipients with advanced diseases (P = 0.032). We concluded that with current management, PTLDs were efficiently controlled, but EBV reactivation still had a multifactorial impact on transplant outcomes. Multicenter prospective studies are warranted to validate these findings.Entities:
Mesh：
Year: 2020 PMID： 32066862 DOI： 10.1038/s41409-020-0831-7
Source DB: PubMed Journal: Bone Marrow Transplant ISSN： 0268-3369 Impact factor: 5.483